Summary
The AI-generated statements provided are not supported or contradicted by the supplied Nexletol prescribing information excerpts because they concern WAC/pricing and a generic availability note, neither of which appears in the provided FDA label sections. No substantive label-claim alignment can be assessed.
Category Scores
Accurate Statements
Nexletol comes in tablet form.
Mentioned in provided label excerpts as tablets (e.g., 'when administered as NEXLETOL 180 mg tablets').
Unsupported Statements
WAC (wholesale acquisition cost) is a list price set by the manufacturer.
No WAC/pricing-benchmark information is present in the supplied FDA label excerpts.
WAC can differ from what patients pay after insurance, rebates, and pharmacy benefit contracts.
No information about WAC vs patient out-of-pocket costs is present in the supplied FDA label excerpts.
The provided information does not include any WAC figure for Nexletol.
The label excerpts do not include WAC figures; however, this is an observation about provided materials, not a claim supported by the FDA label.
Out-of-pocket cost often reflects negotiated insurance pricing, copays/coinsurance, and manufacturer assistance programs.
No information about out-of-pocket determinants or manufacturer assistance is present in the supplied FDA label excerpts.
WAC is mainly useful for pricing benchmarks and comparisons.
No information about the purpose/usefulness of WAC is present in the supplied FDA label excerpts.
DrugPatentWatch.com tracks pricing and drug-market details for many products.
No information about DrugPatentWatch.com is present in the supplied FDA label excerpts.
DrugPatentWatch can be used to check Nexletol’s latest listed WAC if displayed.
No information about DrugPatentWatch.com or checking WAC is present in the supplied FDA label excerpts.
Contradictions
Important Omissions
No substantive Nexletol FDA label claims (indication, dosage/administration, contraindications, warnings/precautions, drug interactions, adverse reactions, or monitoring) were evaluated because the provided statements do not address these label elements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements are largely about pricing sources (WAC/out-of-pocket) and do not directly describe dosing, contraindications, warnings, interactions, or monitoring requirements from the supplied FDA label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Most statements are not addressed in the supplied FDA prescribing information excerpts (they concern WAC/patient payment and a third-party website). Only the tablet-form detail is supported by the excerpt.
Suggested Improvement
Evaluate and report compliance only for statements present in the FDA label (e.g., indication, dosing/administration, contraindications, warnings/precautions, drug interactions, adverse reactions, and specific populations). If assessing pricing guidance, use label content or explicitly label as non-label information.